PT - JOURNAL ARTICLE AU - Yu-Hung Wang AU - Chien-Chin Lin AU - Chia-Lang Hsu AU - Sheng-Yu Hung AU - Chi-Yuan Yao AU - Sze-Hwei Lee AU - Cheng-Hong Tsai AU - Hsin-An Hou AU - Wen-Chien Chou AU - Hwei-Fang Tien TI - Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA <em>KIAA0125</em> AID - 10.1101/2020.08.21.20179267 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.21.20179267 4099 - http://medrxiv.org/content/early/2020/08/24/2020.08.21.20179267.short 4100 - http://medrxiv.org/content/early/2020/08/24/2020.08.21.20179267.full AB - Expression of long non-coding RNA KIAA0125 has been incorporated in various gene expression signatures for prognostic prediction in acute myeloid leukemia (AML) patients, yet its functions and clinical significance remain unclear. This study was aimed to investigate the clinical and biological characteristics of AML bearing different levels of KIAA0125. We profiled KIAA0125 expression levels in bone marrow cells from 347 de novo AML patients and found higher KIAA0125 expression was closely associated with FLT3-ITD, RUNX1, and DNMT3A mutations, and M1 subtype by the French-American-British classification, but inversely correlated with t(8;21) and t(15;17). Among the 227 patients who received standard chemotherapy, those with higher KIAA0125 expression had a lower complete remission rate, shorter overall survival (OS) and disease-free survival (DFS) than those with lower expression. The prognostic significance was validated in both TCGA and GSE12417 cohorts. Subgroup analyses showed that higher KIAA0125 expression also predicted shorter DFS and OS in patients with normal karyotype or non-M3 AML. In multivariable analysis, higher KIAA0125 expression remained an adverse risk factor independent of age, WBC counts, karyotypes, and mutation patterns. Bioinformatics analyses revealed that higher KIAA0125 expression was associated with hematopoietic and leukemic stem cell signatures and ATP-binding cassette transporters, two predisposing factors for chemoresistance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by grants from Ministry of Health and Welfare, Taiwan (project number: MOHW107-TDU-B-211-114009) and Ministry of Science and Technology, Taiwan (project number: MOST 107-2314-B-002-013 and MOST 108-2314-B-002-011).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the National Taiwan University Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw and normalized microarray data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE68469 and GSE71014). https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68469 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71014